{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 21 June 2007\line \line {\b Roche 
establishes Viracept Patient Registries in the interest of patient care} \line Viracept 
license temporarily suspended pending review by authorities\line \line Roche, in 
agreement with EMEA, will establish Viracept Patient Registries in order to register and closely follow 
patients who may have been exposed to a chemical impurity in their Viracept HIV formulations. The registries 
are part of the follow up measures being taken by Roche after the product recall of all formulations 
of Viracept initiated on June 6th following the discovery of an impurity known as EMS (ethyl methansulphonate). 
The US, Canada and Japan are not affected. \line Viracept\u8217?s licence is being suspended in 
Europe whilst further reviews are undertaken. In parallel, Roche will carry out a series of additional 
studies in order to further understand the potential effects of EMS and take measures necessary to ensure 
that future batches of Viracept are in line with specifications for EMS to be agreed with EMEA.\line \line "We 
take the welfare of patients extremely seriously. With the knowledge we have to date, we consider the 
risk to patients to be low, however we want to be sure patients can be followed and these registries 
will allow us to do just that ," says William B. Burns, CEO Pharmaceuticals Division of Roche. 
"The root cause of the elevated levels of impurity observed recently has been identified and we 
are following up on the agreed actions with EMEA".\line \line {\b Roche 
actions} \line In collaboration with the Health Authorities, Roche\par}{\pard\f0\li440\ri0\sl360\fs22 - initiated 
the Viracept recall as soon as the presence of elevated levels of the impurity was determined\par}{\pard\f0\li440\ri0\sl360\fs22 - assessed 
the level of impurity in finished stock that has already been supplied into countries \par}{\pard\f0\li440\ri0\sl360\fs22 - is 
in discussions with national health authorities, health care providers, patient groups and NGOs to manage 
the recall\par}{\pard\f0\li440\ri0\sl360\fs22 - is conducting additional research in order to 
further understand the effects of EMS \par}{\pard\f0\li440\ri0\sl360\fs22 - is establishing Viracept 
Patient Registries to register patients who may have been exposed to elevated levels of EMS as well 
as pregnant women and all children who have ever been exposed to Viracept, including those exposed in 
utero\par}{\pard\f0\li440\ri0\sl360\fs22 - is working with authorities to address outstanding 
manufacturing issues\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 Roche actively pursues all of 
these 
activities but reconfirms that they will not have an impact on the financial guidance.\line \line For 
further information about the Viracept recall, please see the website page www.roche.com/med-cor-2007-06-06b\line \line Further 
information about the Viracept Patient Registries will be released as soon as it is finalized.\line \line {\b About 
Viracept} \line Viracept (nelfinavir), a protease inhibitor is supplied by Roche outside 
the US, Japan and Canada. Viracept was first introduced by Roche in 1998. \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s 
biggest biotech company and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and 
transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune 
diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals 
Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion 
Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances 
with numerous partners, including majority ownership interests in Genentech and Chugai. Roche\u8217?s Diagnostics 
Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products 
and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further 
information, please visit our website at www.roche.com (http://www.roche.com). \line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}